Stem cell trial offers hope to patients vision (Reuter)
WASHINGTON (Reuters)-Christopher Goodrich, Portland, Oregon, can't wait for a needle in his eyes.
Goodrich was expected to be one of the first patients were enrolled in clinical trial this only a sound States food and drug administration, only the second judgment approved anywhere in the world test globil human milk stem in the people.
Advanced cell technology, a Massachusetts-based company biotechnologie did evil to bring globil human milk stem in the lab to the clinic, recrutement 12 patients start in Oregon, Massachusetts and eye condition called scarce Stargardt (k will be put to death.
Goodrich, 55, retired last year of his work as Coordinator for services to the University of Portland State when Stargardt (k death completely inexplicable and suddenly take a turn for the worse.
Like most patients Goodrich, saw the vision, it gets worse steadily from his earliest days in adults.
"Glasses help very, very little," Goodrich said in an interview by telephone.
Dégénérescence "(that is, you know what center went in your eye, who took all the réglage? Red blood cells, causing their death. You know a explosion fusil together? That is what I see. It is through the hole in the rock, I might see something from 24 down from my eyes, my head, I can't see it. "
His infuriating and Goodrich would do something to recover, even allow ophthalmologist for poker a needle in his eyes and perfusion globil human stem letter in that ACT will replace the residence and they see red blood cells.
'' I made a list of all I would like to be able to do and everything I would like to have a right to see, "Goodrich said.
WHO YOUR EYES THE DISEASE AKLÈ
This is the most immediate promise of human embryonic stem cell research--that this package immature red blood cells can be coaxed to down the road to become a great tissue, and in the process to other red blood cells to grow and renouvellement.
Advanced cell technology Products is a letter stem cell trained to become a cell rétinale.
The first clinical trial, only thousands of red blood cells what they are doing injecté in one eye of each volunteer, especially to check to see that in security.
ACT the doctor Robert Lanza said doctors who took part in the process will be able to watch father in one, for it is possible to stare at. see red blood cells are not going up to the retina.
And it would be possible to check one vision in two patients, to see if he improve.
Stargardt's touch only 30,000 to 50,000 Americans, according to the American Macular Degeneration Foundation, but ACT sights fixed on a larger market survey if this success--related to age (dégénérescence.
Condition double touch more than 30 million people worldwide and is a leading cause of Blindness in people over 60 in the United States.
Goodrich was a patient of Dr. Peter Francis Health & Science University, Oregon, who will be one of the investigators on ACT lawsuit. But Lanza said all patients will have to undergo a process of joy.
(Modification not says Cynthia Osterman)
Comments
Post a Comment